Does Medicare Cover Zepbound? What You Need to Know in 2026

As of mid-2026, traditional Medicare (Original Medicare) does not cover Zepbound for weight loss under standard Part D drug benefits. However, there is now a new CMS Medicare GLP-1 Bridge Program that may allow eligible Medicare patients to get Zepbound for as little as $50 per month. The catch is that qualifying for this program is more complicated than simply getting a prescription from your doctor. In this article, I will break down exactly what Medicare does and does not cover, how the Bridge Program works, and what your realistic options are if you are a Medicare patient who wants access to Zepbound.

I am Dr. Matthew Weiner, a bariatric surgeon with over 20 years of experience and more than 4,000 surgeries performed. My team and I at Pound of Cure Weight Loss work with Medicare patients regularly, and we have been closely following the changes in GLP-1 medication coverage as they develop.

What Is Zepbound and Why Do Medicare Patients Want It?

Zepbound (tirzepatide) is an FDA-approved medication for chronic weight management. It belongs to a class of medications known as GLP-1 receptor agonists, though technically Zepbound is a dual GIP/GLP-1 receptor agonist. Clinical trials have shown that tirzepatide can produce significant weight loss, often in the range of 20-25% of total body weight, which makes it one of the most effective weight loss medications available.

For Medicare patients who struggle with obesity and related conditions like type 2 diabetes, sleep apnea, fatty liver disease, and cardiovascular disease, access to Zepbound could be life-changing. The problem has always been cost and coverage.

Why Has Medicare Historically Not Covered Weight Loss Medications?

Medicare Part D has historically excluded coverage for medications prescribed specifically for weight loss. This exclusion dates back to the original Medicare statute, which categorized weight loss drugs alongside cosmetic drugs and other categories that Congress deemed non-essential. This meant that even as highly effective medications like Wegovy and Zepbound came to market, Medicare beneficiaries were left without coverage.

This is different from how Medicare handles tirzepatide when it is prescribed as Mounjaro for type 2 diabetes. If you have type 2 diabetes, Medicare Part D may cover Mounjaro (the same active ingredient as Zepbound) because it is being used for diabetes management rather than weight loss. The distinction is entirely about the indication, not the medication itself.

What Is the CMS Medicare GLP-1 Bridge Program?

The CMS Medicare GLP-1 Bridge Program is a new pathway that may allow Medicare patients to access GLP-1 medications like Zepbound and Wegovy at a dramatically reduced cost of approximately $50 per month. This program represents a significant shift in how CMS is approaching obesity treatment for Medicare beneficiaries.

On a recent episode of The Pound of Cure Podcast titled “Medicare GLP-1 Bridge Program Explained: $50 Wegovy & Zepbound Access,” our nurse practitioner Deidre walked through the eligibility requirements in detail. The key takeaway from that conversation is that this process is more complicated than many patients expect. You cannot simply ask your doctor for a Zepbound prescription and get it for $50. There are specific eligibility criteria that must be met, and Medicare Part D coverage plays a central role in determining whether you qualify.

Who May Qualify for $50 Zepbound Through the Bridge Program?

Eligibility for the Medicare GLP-1 Bridge Program depends on several factors. While I cannot list every specific requirement (because CMS criteria can change and individual circumstances vary), the general framework involves:

• Having Medicare Part D coverage. This is a fundamental requirement. If you do not have Part D prescription drug coverage, the Bridge Program pathway may not be available to you.
• Meeting specific medical criteria. The program is not open to everyone who wants to lose weight. There are clinical thresholds that must be documented.
• Working with a provider who understands the process. This is where things get tricky. Many primary care doctors are not familiar with the Bridge Program requirements, and the application process requires careful documentation.

The important thing to understand is that qualifying takes work. It is not automatic, and it is not guaranteed. But for patients who do meet the criteria, getting Zepbound for $50 per month is a real possibility.

How Has Medicare Coverage for GLP-1 Medications Changed Recently?

Coverage has been expanding, particularly for Medicare Advantage plans. In our practice, we have seen meaningful improvements over the past year. Our nurse practitioner Deidre has reported expanded coverage for Medicare Advantage patients, especially when GLP-1 medications are prescribed for conditions beyond just weight loss.

For example, Wegovy received FDA approval for metabolic dysfunction-associated steatohepatitis (fatty liver disease), and we have had success getting approvals through that indication. The criteria require something called a FIB-4 test that shows moderate fibrosis, but Deidre has found this pathway to be more successful than previous cardiovascular-based criteria (which required a history of heart attack, stroke, or peripheral arterial disease).

We also expect to see expanded coverage in the near future for Medicare and Medicare Advantage patients with renal disease and more moderate cardiovascular conditions. These expanded indications could open the door for more patients to access both Wegovy and Zepbound through their Medicare coverage.

Medicare Advantage vs. Original Medicare: What Is the Difference for Zepbound Coverage?

This distinction matters a lot. Original Medicare (Parts A and B, plus a standalone Part D plan) and Medicare Advantage plans (Part C) handle prescription drug coverage differently.

Medicare Advantage plans are offered by private insurance companies and often include Part D drug coverage as part of the plan. These plans have more flexibility in what they cover, and we have seen some Medicare Advantage plans expand their GLP-1 coverage more aggressively than Original Medicare Part D plans.

If you have a Medicare Advantage plan, it is worth checking with your plan specifically about Zepbound coverage. The answer may surprise you, especially if you have documented comorbid conditions like sleep apnea, fatty liver, or cardiovascular disease.

What If You Have Medicare and Cannot Get Zepbound Covered?

If the Bridge Program does not apply to your situation and your Medicare plan will not cover Zepbound, you still have options. Here is what I tell my patients:

Consider the Diabetes Indication

If you have type 2 diabetes, your doctor may be able to prescribe Mounjaro (the diabetes-branded version of tirzepatide) instead of Zepbound. Because Mounjaro is prescribed for diabetes management, it falls under standard Part D coverage and may be covered by your plan. The medication is identical. The only difference is the brand name and the FDA-approved indication.

Look at Manufacturer Savings Programs

Eli Lilly (the maker of Zepbound) has periodically offered savings programs and coupons, though these programs have restrictions and may not always apply to Medicare patients. It is worth checking the manufacturer’s website for current offers, but be aware that federal law restricts how manufacturer coupons can be used with Medicare.

Work with a Specialized Provider

At Pound of Cure Weight Loss, we offer creative strategies to help patients access GLP-1 medications at lower costs. We only prescribe FDA-approved medications purchased from pharmacies (we do not sell or prescribe compounded medications), and we always try to work with your insurance first. But when insurance falls short, we have strategies that can bring costs down significantly.

Consider Bariatric Surgery

Here is something most people do not realize: Medicare generally does cover bariatric surgery for qualifying patients. If you have a BMI of 35 or higher with obesity-related health conditions, procedures like gastric sleeve and gastric bypass are typically covered by Medicare.

As a bariatric surgeon, I have seen the combination of surgery and GLP-1 medications produce remarkable results. Surgery addresses the hormonal drivers of obesity by lowering your body weight set point, and when combined with GLP-1 medications (even at lower doses), the results can be outstanding. Many of our patients use this combined approach.

How Much Does Zepbound Cost Without Insurance?

Without any insurance coverage or discount programs, Zepbound’s list price has been over $1,000 per month. This is obviously prohibitive for most people, which is why the coverage question matters so much.

For patients who do not have insurance coverage, we have developed approaches at our practice that can reduce costs substantially. We do not prescribe compounded versions of these medications because we believe in using FDA-approved products with verified potency and safety. But there are legitimate ways to reduce what you pay.

Is the $50 Zepbound Through Medicare Too Good to Be True?

I understand the skepticism. When patients hear they might be able to get a medication that normally costs over $1,000 per month for just $50, it sounds unrealistic. But the Medicare GLP-1 Bridge Program is a real CMS initiative. The key is understanding that:

1. Not everyone will qualify
2. The application process requires proper documentation
3. You need a provider who knows how to work within the system
4. Having Medicare Part D is essential

If you are a Medicare patient interested in Zepbound, I strongly recommend listening to our podcast episode on this topic, where Deidre goes into much more detail about the practical steps involved.

What About GLP-1 Microdosing for Medicare Patients?

One approach we have been using more frequently at our practice is GLP-1 microdosing. Rather than escalating to the highest manufacturer-recommended dose (which is how clinical trials are typically designed), we work with patients to find the lowest effective dose that produces good results with fewer side effects.

This matters for Medicare patients for two reasons. First, lower doses mean lower medication costs if you are paying out of pocket. Second, many patients simply do not need the maximum dose to achieve meaningful weight loss, especially when they combine the medication with proper nutritional changes.

We discussed this approach in detail on a recent Pound of Cure Podcast episode about GLP-1 microdosing, and it is becoming an increasingly important part of how we practice obesity medicine.

The Big Picture: Medicare and Obesity Treatment in 2026

We are at an inflection point. The science is clear that obesity is a chronic disease driven by hormonal and neurological factors, not a failure of willpower. Medications like Zepbound are among the most effective treatments ever developed for this condition. And yet, the largest insurance program in the country has been slow to provide coverage.

The Bridge Program is a step forward. The expanded indications for GLP-1 medications (sleep apnea, fatty liver, cardiovascular disease, renal disease) are creating more pathways to coverage. And the political and public health pressure to cover these medications continues to build.

I expect coverage to continue expanding, but I also know that waiting for perfect insurance coverage is not a realistic strategy for most patients who are suffering right now. That is why we focus on finding solutions that work today, whether that means the Bridge Program, creative cost strategies, bariatric surgery, nutritional changes, or a combination of all of these.

What Should You Do Next?

If you are a Medicare patient interested in Zepbound, here are the concrete steps I recommend:

1. Confirm your Part D coverage. Check your Medicare plan to see if you have Part D prescription drug benefits and what formulary restrictions apply.
2. Document your medical conditions. Make sure your medical records clearly reflect any obesity-related conditions like type 2 diabetes, sleep apnea, fatty liver disease, or cardiovascular disease. These conditions can open doors to coverage.
3. Talk to a provider who specializes in obesity medicine. This is not something your regular primary care doctor may be equipped to handle. The documentation, prior authorization process, and knowledge of alternative pathways require specialized experience.
4. Consider all your options. Zepbound is one tool in the toolbox. Bariatric surgery, nutritional counseling, and other GLP-1 medications may also be part of your best treatment plan.

At Pound of Cure Weight Loss, we work with patients across the country through both in-person and telemedicine visits. If you have questions about your specific Medicare coverage or want to find out whether you qualify for the Bridge Program, our team can help you figure that out.